BIRC5 and neoplasm: TAA’s, such as survivin, provide the opportunity to develop immunotherapy, targeting a fixed set of peptides that could be broadly administered to breast cancer patients without the need for patient-specific tumor gene sequencing and personalized immunotherapy.